These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Exosomes derived from bone marrow mesenchymal stem cells inhibit human aortic vascular smooth muscle cells calcification via the miR-15a/15b/16/NFATc3/OCN axis.
    Author: Luo F, Guo W, Liu W.
    Journal: Biochem Biophys Res Commun; 2022 Dec 20; 635():65-76. PubMed ID: 36257194.
    Abstract:
    Cardiovascular events among patients with chronic kidney disease (CKD) are associated with vascular calcification (VC). Nevertheless, the process of vascular calcification is complicated. A mechanism of VC is cellular osteogenic transdifferentiation. The mechanism through which bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exo) relieve VC is unknown. For the purpose of this study, we used human aortic vascular smooth muscle cells (HA-VSMCs) stimulated by high phosphate to investigate how BMSC-Exo works. Cell calcification was detected by Alizarin red S staining, AKP activity analysis, and the Ca2+ concentration test. The dual-luciferase reporter gene assays were utilized to confirm the targeting link between miR-15a-5p, miR-15b-5p, and miR-16-5p (miR-15a/15b/16) and nuclear factors of activated T cells 3 (NFATc3). The expression of osteogenic transdifferentiation biomarkers was detected using Western blot and RT-qPCR. Based on our findings, miR-15a/15b/16 plays a crucial role in BMSC-Exo's inhibitory effects on calcification and osteogenic transdifferentiation. We then confirmed that miR-15a/15b/16 specifically target the 3'UTR of NFATc3 mRNA and that three miRNAs are more effective than one miRNA. Moreover, we found that down-regulation of NFATc3 could inhibit osteocalcin (OCN) expression, thereby inhibiting the osteogenic transdifferentiation and calcification of HA-VSMCs. This study found that BMSC-Exo plays a role in calcification inhibition by transferring miR-15a/15b/16 and inhibiting their common target gene NFATc3, which down-regulates OCN expression and thus inhibits HA-VSMC osteogenic transdifferentiation. This study identifies a novel target for therapeutic therapy of CKD-VC.
    [Abstract] [Full Text] [Related] [New Search]